carboplatin doxorubicin versu cisplatin doxorubicin cyclophosphamid random trial stage iii-iv epitheli ovarian carcinoma sixty-four patient stage iii-iv epitheli ovarian carcinoma cisplatin cddp mg/mq mg/mq mg/mq pac mg/mq mg/mq cac equitox dose cycl drug dosag hematolog toxic previou cours cac pac patient dosag reduct second cours cac pac relev neuro-nephrotox cddp hydrat forc diuresi carboplatin rapid intraven IV infus cycl respons rate superimpos cac pac patholog complet respons pcr cac pac patient cm residu diseas pac pcr cac median surviv progression-fre surviv pfss month pac month cac differ signific conclus trial equitox dose pac cac result similar respons rate pf surviv 